Pegassist
Where Patients Matter
Type a Question Go
Brought to you by the makers of PEGASYSŪ (Peginterferon alfa-2a)
Healthcare Professionals
Patient Education Materials
24-7 Nurse Support
Support Specifically Designed for Your Use During Treatment with PEGASYS
Already a Member? Login Now
Forgot
Password?
Not a member? Sign up is simple
Quick Tip
Wear shoes with thick flexible soles that will cushion your feet and absorb shock.
Check with your doctor.
Learning About Hepatitis C
Why Is My Genotype Important? Your genotype is important because it influences your treatment plan and response to therapy. If you don't know the genotype of the virus causing your infection, use the Questions Worksheet so you can ask your doctor at your next appointment.

Only your doctor can tell you how your genotype relates to your treatment with PEGASYS and COPEGUS® (Ribavirin, USP), but generally people with genotypes 1 and 4 require 48 weeks of treatment, and people with genotypes 2 and 3 need only 24 weeks of treatment.

The following general guidelines are usually followed.

For patients with genotypes 1 and 4 hepatitis C:

  • Start therapy with PEGASYS injections at a dose of 180 mcg weekly.
  • Take COPEGUS tablets in 2 divided doses totaling 1000 or 1200 mg daily, depending on body weight. Patients who weigh less than 75 kilograms (165 pounds) normally receive the lower dose.
  • If good results are seen during weeks 12 to 24 (as determined by your doctor), the therapy will likely continue for a total of 48 weeks, with periodic lab testing.
  • If your doctor does not see progress, he or she may tell you to stop therapy.

For patients with genotypes 2 and 3 hepatitis C:

  • Start therapy with PEGASYS injections at a dose of 180 mcg weekly.
  • Take COPEGUS tablets in 2 divided doses totaling 800 mg daily.
  • Stop therapy after 24 weeks and assess results.

The treatment time is normally shorter and the dose of COPEGUS is usually lower for patients with genotypes 2 and 3, because clinical studies showed that this course of therapy was just as effective as 48 weeks of treatment for these patients.

Again, these are general guidelines—your healthcare team will determine how you need to be treated.

During your therapy, your doctor may adjust your dose of PEGASYS or COPEGUS if you have certain side effects. Be sure to tell your doctor or nurse how you are feeling, and provide details even if you are not sure that they are related to hepatitis C or your treatment.

If a blood test shows that the hepatitis C genetic material has remained absent from your blood 6 months after the end of therapy, this is very good news: in studies, fewer than 1% of patients had a recurrence of infection after this point.

Back to Top

 


Safety Information

What is PEGASYS?

PEGASYS is a medicine used to treat some adults who have hepatitis C and signs of liver damage. PEGASYS works to reduce the amount of virus in your blood, helping your body fight the virus.

PEGASYS® (Peginterferon alfa-2a), like other alpha interferons, can cause fatal or make life-threatening problems worse (like mental, immune system, heart, liver, lung, intestinal and infections). Your doctor should monitor you during regular visits. If you show signs or symptoms of these conditions, your doctor may stop your medication. In most patients, these conditions get better after you stop taking PEGASYS (see medication guide for more information and warnings).

What is COPEGUS?

COPEGUS is a medicine that works by slowing down the growth of the virus. COPEGUS should be taken with PEGASYS to fight the virus. Do not take COPEGUS by itself.

COPEGUS® (Ribavirin, USP) can be extremely harmful and cause birth defects in an unborn baby. Female patients and the female partners of male patients should avoid getting pregnant. Ribavirin is known to cause anemia (low red blood cells), which can make heart disease worse. Also, ribavirin can harm your DNA and possibly cause cancer (see medication guide for more information and warnings).

Who should not take PEGASYS and COPEGUS?

Do not take PEGASYS alone or with COPEGUS if:

  • You are pregnant or your partner is pregnant
  • You or your partner plans to get pregnant during therapy or within 6 months after treatment ends
  • You are breastfeeding
  • You have hepatitis caused by your immune system (autoimmune hepatitis)
  • You have unstable or severe liver disease before or during treatment
  • You are allergic to alpha interferons or any of the ingredients in PEGASYS and COPEGUS
  • You have abnormal red blood cells (caused by conditions like sickle-cell anemia or thalassemia major)

What if I am pregnant or thinking about having a baby?

If you are a woman who could get pregnant, you must take pregnancy tests before, during and for 6 months after treatment ends to make sure you are not pregnant.

During treatment and for 6 months after treatment, female and male patients must:

  • Use two forms of birth control (one being a condom with spermicide)
  • Tell your doctor right away if you or your partner becomes pregnant. You or
    your doctor should also call the Ribavirin Pregnancy Registry at 1-800-593-2214

What medication should I avoid when I am taking PEGASYS and COPEGUS?

You should not take didanosine with COPEGUS. Talk to your doctor about all medications that you are taking.

What are the possible side effects?

The most common side effects of PEGASYS and COPEGUS are:

  • Flu-like symptoms (including fever, chills, muscle aches, joint pain, headaches)
  • Tiredness
  • Upset stomach (like nausea, taste changes, diarrhea)
  • Blood sugar problems (may lead to diabetes)
  • Skin problems (like rash, dry or itchy skin, redness and swelling at injection site)
  • Hair loss (temporary)
  • Trouble sleeping

The most serious side effects of PEGASYS and COPEGUS are:

  • Risks to pregnancies
  • Mental health problems (such as irritability, depression, anxiety, aggressiveness, trouble with drug addiction or overdose, thoughts about suicide, suicide attempts, suicide and thoughts about homicide)
  • Blood problems (like a drop in blood cells leading to increased risk for infections, bleeding and/or heart or circulatory problems)
  • Infections (which sometimes cause death)
  • Lung problems (like trouble breathing, pneumonia)
  • Eye problems (like blurred vision, loss of vision)
  • Autoimmune problems (such as psoriasis, thyroid problems)
  • Heart problems (including chest pain and, rarely, a heart attack)
  • Liver problems (rarely, liver function worsens). Patients with both the hepatitis C virus and HIV can have an increased chance of having liver failure during PEGASYS treatment. Change in a blood test that measures liver inflammation occurs more often in patients with hepatitis B. If you have a rise in this blood test you may need to be watched more closely with additional blood tests.

Tell your doctor immediately if you think you or your partner may be pregnant or if any of these symptoms occur.

This information does not take the place of talking to your healthcare professional about your medical condition or your treatment.

Please see the medication guides and complete product information for PEGASYS and COPEGUS.

 

THIS SITE INTENDED FOR U.S. AUDIENCES ONLY

For more information about PEGASYS, contact your physician or other healthcare professional.

Roche
Copyright © 2003-2008 Hoffmann-La Roche Inc. All rights reserved. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and PRIVACY Statement. Because Pegassist.com offers some unique features and options, Roche provides additional protection tailored to those items. Click here to read Additional Details about your Privacy.
   
eHealthcare Leadership Awards 2004 Winner, Gold Award: Best Care/Disease Management Site Brought to you by the makers of PEGASYS® (Peginterferon alfa-2a)
Gold Award:
Best Care/Disease
Management Site